<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32443324</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>06</Month>
        <Day>15</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>14</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1536-5964</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>99</Volume>
            <Issue>20</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>May</Month>
            </PubDate>
          </JournalIssue>
          <Title>Medicine</Title>
          <ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Trihexyphenidyl induced malignant hyperthermia in a patient with Parkinson's disease complicated with pneumonia: A case report.</ArticleTitle>
        <Pagination>
          <StartPage>e20129</StartPage>
          <MedlinePgn>e20129</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">e20129</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000020129</ELocationID>
        <Abstract>
          <AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Drug-induced fever is easy to overlook in respiratory departments. High fever is a rare side effect of trihexyphenidyl, which can be used clinically to treat Parkinson's disease. Syndrome of inappropriate antidiuretic hormone secretion (SIADH) is a group of clinical syndromes caused by various diseases, resulting in water retention and refractory hyponatremia. However, pneumonia combined with malignant hyperthermia and SIADH has rarely been reported. We describe an unusual case of malignant hyperthermia and refractory hyponatremia due to trihexyphenidyl adverse reaction.</AbstractText>
          <AbstractText Label="PATIENT CONCERNS" NlmCategory="METHODS">Fifty-five-year-old male with pneumonia presented with malignant hyperthermia and refractory hyponatremia has a history of Parkinson's disease.</AbstractText>
          <AbstractText Label="DIAGNOSIS" NlmCategory="METHODS">Early considerations related the described hyperthermia findings to the manifestations of pneumonia. However, the last findings were due to trihexyphenidyl adverse reaction.</AbstractText>
          <AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">Broad-spectrum antibiotics, oral and intravenous supplement of concentrated sodium chloride, drug, and physical cooling.</AbstractText>
          <AbstractText Label="OUTCOMES" NlmCategory="RESULTS">The patient survived. During the 3-month follow up, the patient was no recurrence of fever or hyponatremia.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">High fever and SIADH can be a rare adverse reaction to trihexyphenidyl. Therefore, possible drug factors should be considered in the case. Consideration of other possible causes can improve early diagnosis and treatment of patients with fever of unknown origins.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zhao</LastName>
            <ForeName>Jun</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Geriatrics, National Clinical Key Specialty, Guangzhou First People's Hospital, School of Medicine, South China University of Technology.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Guangzhou First People's Hospital, Guangzhou Medical University.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Gang</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Geriatrics, National Clinical Key Specialty, Guangzhou First People's Hospital, School of Medicine, South China University of Technology.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Guangzhou First People's Hospital, Guangzhou Medical University.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Feng</LastName>
            <ForeName>Congrui</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Geriatrics, National Clinical Key Specialty, Guangzhou First People's Hospital, School of Medicine, South China University of Technology.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Guangzhou First People's Hospital, Guangzhou Medical University.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Yuluo</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Geriatrics, National Clinical Key Specialty, Guangzhou First People's Hospital, School of Medicine, South China University of Technology.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Guangzhou First People's Hospital, Guangzhou Medical University.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kang</LastName>
            <ForeName>Yanhong</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Respiration, The First Affiliated Hospital/School of Clinical Medicine of Guangdong Pharmaceutical University, Guangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Feng</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Geriatrics, National Clinical Key Specialty, Guangzhou First People's Hospital, School of Medicine, South China University of Technology.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Guangzhou First People's Hospital, Guangzhou Medical University.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ma</LastName>
            <ForeName>Wei</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Geriatrics, National Clinical Key Specialty, Guangzhou First People's Hospital, School of Medicine, South China University of Technology.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Guangzhou First People's Hospital, Guangzhou Medical University.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Medicine (Baltimore)</MedlineTA>
        <NlmUniqueID>2985248R</NlmUniqueID>
        <ISSNLinking>0025-7974</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>6RC5V8B7PO</RegistryNumber>
          <NameOfSubstance UI="D014282">Trihexyphenidyl</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007010" MajorTopicYN="N">Hyponatremia</DescriptorName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008305" MajorTopicYN="N">Malignant Hyperthermia</DescriptorName>
          <QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011014" MajorTopicYN="N">Pneumonia</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014282" MajorTopicYN="N">Trihexyphenidyl</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors have no conflicts of interest to disclose.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>5</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>5</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>6</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32443324</ArticleId>
        <ArticleId IdType="pmc">PMC7254568</ArticleId>
        <ArticleId IdType="doi">10.1097/MD.0000000000020129</ArticleId>
        <ArticleId IdType="pii">00005792-202005150-00040</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Durack DT, Street AC.
Fever of unknown origin—reexamined and redefined. Curr Clin Top Infect Dis
1991;11:35–51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1651090</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jabbari B, Scherokman B, Gunderson CH, et al. 
Treatment of movement disorders with trihexyphenidyl. Mov Disord
1989;4:202–12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2779591</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vestberg F.
Treatment of parkinsonism with benzhexole (Artane and Artane-sequel). Ugeskrift for laeger
1967;129:1511–2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">5594302</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pakkenberg H.
Treatment of Parkinsonism with artane and slow release artane. Dan Med Bull
1966;13:204.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">5978771</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blumensohn R, Razoni G, Shalev A, et al. 
Bradycardia due to trihexyphenidyl hydrochloride. Drug Intell Clin Pharm
1986;20:786–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3769769</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trabelsi S, El Aidli S, Kastalli S, et al. 
Bullous erythema multiform induced by trihexyphenidyl. Therapie
2006;61:537–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17348612</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ellison DH, Berl T.
Clinical practice. The syndrome of inappropriate antidiuresis. N Engl J Med
2007;356:2064–72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17507705</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hannon MJ, Thompson CJ.
The syndrome of inappropriate antidiuretic hormone: prevalence, causes and consequences. Eur J Endocrinol
2010;162: Suppl 1: S5–12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20164214</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Velamoor VR, Norman RM, Caroff SN, et al. 
Progression of symptoms in neuroleptic malignant syndrome. J Nerv Ment Dis
1994;182:168–73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7906709</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Berardi D, Troia M, Veronesi L, et al. 
Neuroleptic malignant syndrome. Case reports. Minerva Psichiatrica
1994;35:199–219.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7861943</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rajesh KM, Sinnathamby V, Sakthi AN.
Neuroleptic malignant syndrome masked by cerebral malaria. BMJ Case Rep
2013;2013.doi: 10.1136/bcr-2013-009061.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3670014</ArticleId>
            <ArticleId IdType="pubmed">23704432</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Andreassen MD, Pedersen S.
Malignant neuroleptic syndrome. A review of epidemiology, risk factors, diagnosis, differential diagnosis and pathogenesis of MNS. Ugeskrift for laeger
2000;162:1366–70.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10745673</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Caroff SN, Mann SC.
Neuroleptic malignant syndrome. Med Clin North Am
1993;77:185–202.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8093494</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kwok JS, Chan TY.
Recurrent heat-related illnesses during antipsychotic treatment. Ann Pharmacother
2005;39:1940–2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16174785</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schwartz WB, Bennett W, Curelop S, et al. 
A syndrome of renal sodium loss and hyponatremia probably resulting from inappropriate secretion of antidiuretic hormone. 1957. J Am Soc Nephrol
2001;12:2860–70.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11729259</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peri A, Pirozzi N, Parenti G, et al. 
Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH). J Endocrinol Invest
2010;33:671–82.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20935451</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vantyghem MC, Balavoine AS, Wemeau JL, et al. 
Hyponatremia and antidiuresis syndrome. Annales d’endocrinologie
2011;72:500–12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22119069</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Esposito P, Piotti G, Bianzina S, et al. 
The syndrome of inappropriate antidiuresis: pathophysiology, clinical management and new therapeutic options. Nephron Clin Pract
2011;119:c62–73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21677440</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
